Hiroshige and collaborators found that among mCRPC patients treated with androgen receptor axis-targeted therapies, those with initial sarcopenia showed better PFS rates than their nonsarcopenic counterparts, marking sarcopenia as a potentially favorable prognostic factor in this context [25]. The gene discussed is AR; the disease is sarcopenia.